Can We Actually Find Them

A label narrower than the trial that supported it, and the question no forecast model asks.

When approval defines the market as refractory patients rather than diagnosed ones, the commercial problem stops being demand conversion and becomes patient identification. A label is a market definition, not a regulatory formality, so the capability to find patients has to be built before launch, not after.

Decision context

First emerging company I had joined, and its first commercial product. No other franchise to hide inside, no established channel to inherit, no second chance next quarter.

We came out of an advisory committee with a label narrower than the trial that supported it. The approved patient had to be refractory. The patient we had built the launch to find was not the patient we were allowed to treat.

Why that is harder than it sounds

• A refractory patient is defined by a failure that has to happen first. Not by a diagnosis you can query for. You are looking for people identified by something that already went wrong.
• The diagnosis may sit in a claim nobody in Commercial ever reads. The signal exists. The organization is not built to see it.
• Every commercial assumption built during development pointed at a population the product could no longer be sold into. That is not a plan that needs adjusting. It is a plan that needs replacing, on approval day.

The realization

Until then I had assumed the hard part was converting demand. After it, I understood that the hard part is often finding the patient at all, and that no forecast model asks that question. This is the experience that most changed how I understand healthcare economics, and it is the reason identification became the thing I could not stop thinking about.

What I would do differently

The same answer as the immunology launch, which is why it is the answer. Build the patient identification capability before the launch, not after it.

A label is a market definition, not a regulatory formality. It is the single sentence that decides how many patients your business actually has.

Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.